Advertisement
U.S. Markets open in 6 hrs 57 mins

Checkpoint Therapeutics, Inc. (CKPT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
3.3700+0.0700 (+2.12%)
At close: 04:00PM EST
3.3300 -0.04 (-1.19%)
After hours: 07:06PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close3.3000
Open3.3900
Bid3.3400 x 1000
Ask3.3800 x 1000
Day's Range3.2800 - 3.4850
52 Week Range1.3600 - 3.9700
Volume745,208
Avg. Volume596,733
Market Cap151.71M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-1.7100
Earnings DateNov 11, 2024 - Nov 15, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
  • GlobeNewswire

    Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

    Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation of longer-term data from its pivotal trial of cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, in locally advanced and metastatic cutaneous squamous cell carcinoma (“cSCC”)

  • GlobeNewswire

    Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

    WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 10:00 a.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference. A webcas